

Formulary quarterly impact report

State of New Mexico RMD

Formulary type: Standard with ACSF

Claims Period: September 2023 - December
2023



This report contains confidential and proprietary information of CVS Health and cannot be reproduced, distributed or reprinted without permission from CVS Health. Every effort is made by CVS Caremark and its advisors to maintain the highest level of accuracy in its projections; however, because of the variability of a number of factors, which are not under the control of CVS Caremark, we cannot guarantee the estimated results shown. Tier values of "X" indicate the drug is not part of CVS Caremark's standard formulary. Drug may be subject to PA/medical exceptions process or no drug coverage.
©2023 CVS Health and/or one of its affiliates: Confidential & Proprietary

Formulary quarterly impact report

Current utilization summary

Distinct Utilizers	Rxs	Days	Gross	Net
34,615	254,081	7,520,075	\$38,587,042	\$36,226,404

Estimated impact of formulary update

Change category	Member impact	Distinct utilizers impacted*	Percent (%) total utilizing members impacted	Impacted Rxs	Percent (%) total Rxs impacted
Exclusion	Positive	0	0.00%	0	0.00%
Exclusion	Negative	868	2.51%	1,463	0.58%
Exclusion	Total	868	2.51%	1,463	0.58%
Tier change	Positive	0	0.00%	0	0.00%
Tier change	Negative	3	0.01%	4	0.00%
Tier change	Total	3	0.01%	4	0.00%
Total		871	2.52%	1,467	0.58%

*The sum of distinct utilizers is greater than the Total Impacted Distinct Utilizers due to overlap among positively impacted and negatively impacted products.

Also see disclaimer notes on cover page.
©2023 CVS Health and/or one of its affiliates: Confidential & Proprietary



Formulary quarterly impact report - drug detail

Formulary impact - drug detail

Drug name	Therapeutic class	Change category	Member impact	Current tier	New tier	Utilizers	Rxs	Current gross cost	Current member cost	Current net cost
ALBUTEROL PA	SYMPATHOMIMETICS	Exclusion	Negative	1	X	759	1,100	\$21,537	\$6,882	\$14,656
HUMIRA PEN	ANTI-TNF-ALPHA - MONOCLONAL ANTIBODIES	Exclusion	Negative	2	X	97	329	\$2,343,227	\$7,975	\$2,335,253
HUMIRA	ANTI-TNF-ALPHA - MONOCLONAL ANTIBODIES	Exclusion	Negative	2	X	6	20	\$157,508	\$0	\$157,508
VELPHORO	PHOSPHATE BINDER AGENTS	Exclusion	Negative	2	X	6	10	\$30,682	\$199	\$30,482
EVAMIST TOP	ESTROGENS	Tier Change	Negative	2	3	1	2	\$271	\$81	\$189
IMBRUVICA	ANTINEOPLASTIC ENZYME INHIBITORS	Exclusion	Negative	2	X	1	4	\$20,230	\$6,069	\$14,161
PYLERA	ULCER THERAPY COMBINATIONS	Tier Change	Negative	2	3	1	1	\$1,233	\$95	\$1,138
ZYCLARA PUMP	IMMUNOMODULATING AGENTS - TOPICAL	Tier Change	Negative	2	3	1	1	\$1,177	\$145	\$1,032

Also see disclaimer notes on cover page.

©2023 CVS Health and/or one of its affiliates: Confidential Proprietary

